Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pathology

Decoding Your Pathology: Grades and Subtypes

At a Glance

Chondrosarcoma pathology reports dictate your prognosis and treatment by detailing the tumor's grade and subtype. Conventional tumors are graded 1 to 3 based on aggressiveness. Identifying specific subtypes and IDH1/IDH2 mutations helps confirm the diagnosis and guide your care.

Your pathology report is the most important document in your medical file. It translates the “look” of your tumor cells into a roadmap for your treatment. In chondrosarcoma, the grade (how aggressive the cells appear) and the subtype (the specific flavor of the cancer) dictate your prognosis and the intensity of your care [1][2].

The Three Grades of Conventional Chondrosarcoma

Most chondrosarcomas are “conventional,” meaning they look like typical cartilage but have gone awry. These are graded from 1 to 3 [1]:

  • Atypical Cartilaginous Tumor (ACT) vs. Grade 1 Chondrosarcoma: Under a microscope, these cells look very similar to normal cartilage, but the WHO strictly classifies them based on location due to vastly different risks [3]. If these low-grade cells are in your appendicular skeleton (arms or legs), they are called ACT. They are locally aggressive but rarely spread [1]. However, if identical cells are located in your axial skeleton (pelvis, spine, or skull), they are diagnosed as Grade 1 Chondrosarcoma, because tumors in these locations are much harder to remove and carry a higher risk of local recurrence and worse prognosis [4].
  • Grade 2: These cells show more atypia (abnormal shapes) and higher cellularity (more cells packed together). They have a moderate risk of spreading and require wide surgical margins [1][5].
  • Grade 3: These are high-grade tumors with very irregular cells and often contain necrosis (dead tissue). They are frequently metastatic, meaning they are more likely to spread to the lungs or other bones [1][4].

Non-Conventional Subtypes

While “conventional” is the most common form, about 10-15% of patients have a non-conventional subtype. These often behave differently and may require more intensive treatment [6]:

Subtype Characteristics Outlook
Dedifferentiated (DCS) A “biphasic” tumor where a low-grade tumor suddenly turns into a high-grade, non-cartilage cancer [7]. Very aggressive; often treated with surgery and sometimes chemotherapy [8][9].
Mesenchymal (MCS) A rare, high-grade variant featuring “small round blue cells” and cartilage islands [10]. Often affects younger patients; highly prone to spreading and often requires chemotherapy [11][12].
Clear Cell (CCCS) A rare, low-grade malignant tumor that often appears at the ends of long bones [13]. Generally has a slow course and better survival, though it can recur years later [14][15].

The Role of IDH1 and IDH2 Mutations

Between 50% and 80% of conventional and dedifferentiated chondrosarcomas carry mutations in the IDH1 or IDH2 genes [16][17].

  • Early Event: These mutations happen very early in the tumor’s life [18].
  • Diagnostic Clue: Finding an IDH mutation can help your pathologist confirm that the tumor is indeed a cartilaginous growth, though it cannot distinguish between a benign growth and a malignant one on its own [19][20].
  • Future Targets: While not yet standard of care, new drugs called IDH inhibitors are being studied in clinical trials for patients whose tumors have these specific mutations [21][22].

Pathology Report Completeness Checklist

Ensure your report includes these critical elements for an accurate diagnosis [2][11]:

  1. Subtype: Is it Conventional, Dedifferentiated, Mesenchymal, or Clear Cell?
  2. Grade: Is it ACT/Grade 1, 2, or 3? (Based on the highest grade area found) [23].
  3. Size: The maximum dimension of the tumor in centimeters [5].
  4. Margin Status: Are the edges clear (R0), or is there microscopic (R1) or macroscopic (R2) tumor remaining? [24].
  5. Mitotic Rate: How many cells were actively dividing? [1].
  6. Necrosis: Is there any evidence of dead tumor tissue? [1].
  7. Molecular Testing: Were IDH1/2 or other markers like CDKN2A tested? [16].

Common questions in this guide

What is the difference between an Atypical Cartilaginous Tumor and Grade 1 Chondrosarcoma?
While both look similar under a microscope, the diagnosis depends on where the tumor is located. Low-grade tumors in the arms or legs are called Atypical Cartilaginous Tumors (ACT), whereas those in the pelvis, spine, or skull are classified as Grade 1 Chondrosarcoma due to higher risks.
What does a Grade 3 chondrosarcoma diagnosis mean?
A Grade 3 chondrosarcoma is a highly aggressive tumor with very irregular cells and areas of dead tissue called necrosis. This high-grade classification means the cancer has a higher risk of spreading to the lungs or other bones.
What is a dedifferentiated chondrosarcoma?
Dedifferentiated chondrosarcoma is an aggressive subtype where a low-grade cartilage tumor rapidly changes into a high-grade, non-cartilage cancer. Because it is highly aggressive, it is often treated with intensive surgery and sometimes chemotherapy.
Why do doctors test for IDH1 or IDH2 mutations in chondrosarcoma?
Testing for IDH1 and IDH2 gene mutations helps pathologists officially confirm that the tumor is a cartilaginous growth. While primarily used for diagnosis right now, researchers are also studying new targeted drugs for patients with these specific mutations.
What does an R0 margin status mean on my pathology report?
An R0 margin status means the surgeon successfully removed the entire tumor with a clear border of healthy tissue around it. This indicates that no microscopic cancer cells were left behind at the outer edges of the removed tissue.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the histological grade (1, 2, or 3) of the highest-grade area found in my tumor?
  2. 2.Was my tumor identified as 'Conventional' or one of the non-conventional subtypes like 'Dedifferentiated' or 'Mesenchymal'?
  3. 3.Were my IDH1 and IDH2 mutations tested using Next-Generation Sequencing (NGS) rather than just Immunohistochemistry (IHC)?
  4. 4.What were the surgical margins, and were they 'R0' (no cancer cells at the very edge)?
  5. 5.Does my pathology report mention any 'myxoid' changes or 'necrosis'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    A new scoring system for the grading of conventional chondrosarcoma: Its clinicopathological significance.

    Susuki Y, Yamada Y, Ito Y, et al.

    Pathology, research and practice 2022; (238()):154125 doi:10.1016/j.prp.2022.154125.

    PMID: 36174441
  2. 2

    Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings.

    Kim JH, Lee SK

    Cancers 2023; (15(6)) doi:10.3390/cancers15061703.

    PMID: 36980590
  3. 3

    Chondrosarcoma.

    Weinschenk RC, Wang WL, Lewis VO

    The Journal of the American Academy of Orthopaedic Surgeons 2021; (29(13)):553-562 doi:10.5435/JAAOS-D-20-01188.

    PMID: 33595238
  4. 4

    The role of imaging in differentiating low-grade and high-grade central chondral tumours.

    Sharif B, Lindsay D, Saifuddin A

    European journal of radiology 2021; (137()):109579 doi:10.1016/j.ejrad.2021.109579.

    PMID: 33578088
  5. 5

    Risk factors for metastasis at presentation with conventional chondrosarcoma: a population-based study.

    Song K, Shi X, Liang X, et al.

    International orthopaedics 2018; (42(12)):2941-2948 doi:10.1007/s00264-018-3942-7.

    PMID: 29681020
  6. 6

    Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis.

    Amer KM, Munn M, Congiusta D, et al.

    Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2020; (38(2)):311-319 doi:10.1002/jor.24463.

    PMID: 31498474
  7. 7

    Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.

    Lucas CG, Grenert JP, Horvai A

    Archives of pathology & laboratory medicine 2021; (145(8)):1009-1017 doi:10.5858/arpa.2020-0379-OA.

    PMID: 33147331
  8. 8

    Dedifferentiated chondrsarcoma: a clinicopathologic analysis of 25 cases.

    Cao L, Wu Y, Han SM, et al.

    BMC musculoskeletal disorders 2021; (22(1)):189 doi:10.1186/s12891-021-04053-7.

    PMID: 33588810
  9. 9

    Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials.

    Zając W, Dróżdż J, Kisielewska W, et al.

    Cancers 2023; (15(15)) doi:10.3390/cancers15153924.

    PMID: 37568740
  10. 10

    Periosteal mesenchymal chondrosarcoma of the tibia with multifocal bone metastases: a case report.

    Kumar R, Duran C, Amini B, et al.

    Skeletal radiology 2017; (46(7)):995-1000 doi:10.1007/s00256-017-2626-5.

    PMID: 28352960
  11. 11

    Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.

    Tlemsani C, Larousserie F, De Percin S, et al.

    International journal of molecular sciences 2023; (24(2)) doi:10.3390/ijms24021361.

    PMID: 36674874
  12. 12

    Chemotherapy in dedifferentiated chondrosarcoma: From neoadjuvant to palliative treatment options.

    Remiszewski P, Wąż J, Falkowski S, et al.

    Critical reviews in oncology/hematology 2026; (223()):105297 doi:10.1016/j.critrevonc.2026.105297.

    PMID: 41895355
  13. 13

    Clear cell chondrosarcoma: a review of clinicopathologic characteristics, differential diagnoses, and patient management.

    Alexiev BA, Vormittag-Nocito ER, Peabody TD, et al.

    Human pathology 2023; (139()):126-134 doi:10.1016/j.humpath.2023.06.004.

    PMID: 37805864
  14. 14

    Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.

    Lam SW, van Langevelde K, Suurmeijer AJH, et al.

    Histopathology 2019; (75(6)):843-852 doi:10.1111/his.13952.

    PMID: 31297850
  15. 15

    Dedifferentiated chondrosarcoma with minimal or small dedifferentiated component.

    Dehner CA, Maloney N, Amini B, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022; (35(7)):922-928 doi:10.1038/s41379-022-01008-8.

    PMID: 35115636
  16. 16

    Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma.

    Dermawan JKT, Nafa K, Mohanty A, et al.

    Cancer research communications 2023; (3(3)):431-443 doi:10.1158/2767-9764.CRC-22-0397.

    PMID: 36926116
  17. 17

    Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.

    Denu RA, Yang RK, Lazar AJ, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(23)):4844-4852 doi:10.1158/1078-0432.CCR-23-1703.

    PMID: 37747813
  18. 18

    Enchondromatosis and Growth Plate Development.

    Zhang H, Alman BA

    Current osteoporosis reports 2021; (19(1)):40-49 doi:10.1007/s11914-020-00639-7.

    PMID: 33306166
  19. 19

    BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study.

    Montoya-Cerrillo DM, Evans MG, Elliott A, et al.

    Genes, chromosomes & cancer 2025; (64(9)):e70068 doi:10.1002/gcc.70068.

    PMID: 40944348
  20. 20

    IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.

    Saiji E, Pause FG, Lascombes P, et al.

    Virchows Archiv : an international journal of pathology 2019; (475(5)):625-636 doi:10.1007/s00428-019-02606-9.

    PMID: 31240473
  21. 21

    Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.

    Tap WD, Villalobos VM, Cote GM, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(15)):1693-1701 doi:10.1200/JCO.19.02492.

    PMID: 32208957
  22. 22

    Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.

    Jones RL, Groisberg R, Blay JY, et al.

    Nature communications 2026; (17(1)).

    PMID: 41611702
  23. 23

    The role of grade in local recurrence and the disease-specific survival in chondrosarcomas.

    Laitinen MK, Stevenson JD, Parry MC, et al.

    The bone & joint journal 2018; (100-B(5)):662-666 doi:10.1302/0301-620X.100B5.BJJ-2017-1243.R1.

    PMID: 29701096
  24. 24

    Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature.

    Coşkun HS, Erdoğan F, Büyükceran İ, Dabak N

    Joint diseases and related surgery 2022; (33(2)):440-448.

    PMID: 35852206

This page explains chondrosarcoma pathology terminology for educational purposes. Always consult your oncologist and specialized bone pathologist to interpret your specific report and understand what it means for your treatment.

Get notified when new evidence is published on Chondrosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.